Chemical and pharmaceutical group Bayer of Germany is to invest 140 million Deutschemarks ($92.6 million) in a new technical center at its Wuppertal site in Germany.
Bayer says that it will develop new pharmaceutical active ingredients for worldwide application at the new facilities, which will be more efficient and versatile than those in use at present. The current facilities have been operating since the 1970s. The new facilities will also help to shorten development time for new products.
Horst Meyer, general manager of the business group, described the investment as "another important signal for the future of the Bayer site in Wuppertal, coming as it does shortly after the start of construction work on new chemical-scientific laboratories there."
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze